GlassScriptPhysician profile
Richard B Grabowski
NPI 1194720680
$6,206.47
in general payments reported to CMS, 2019-2025
25 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $133 · 2021: $534 · 2022: $2,291 · 2023: $686 · 2024: $644 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.03 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $2,365.67 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $1,114.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $411.38 | 2019-2025 | |
| Pfizer INC. | $360.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $298.95 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $273.04 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $194.61 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $190.14 | 2023-2024 | Vtama |
| Incyte Corporation | $188.15 | 2023-2025 | Opzelura |
| Ucb, INC. | $142.51 | 2021-2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $131.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $75.94 | 2019-2020 | |
| Revance Therapeutics, INC. | $73.39 | 2024-2025 | Daxxify |
| Leo Pharma INC. | $67.04 | 2019-2020 | |
| Lilly USA, LLC | $66.29 | 2019-2025 | Ebglyss, Taltz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.64 | 2019-2020 | |
| Organogenesis INC. | $31.59 | 2024 | Affinity |
| Allergan, INC. | $29.82 | 2022 | |
| Janssen Biotech, INC. | $28.54 | 2019 | |
| Celgene Corporation | $26.87 | 2019 | |
| Organon LLC | $24.81 | 2025 | Vtama |
| Dermira, INC. | $20.22 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.56 | 2019 | |
| Vyne Pharmaceuticals INC. | $16.99 | 2020 | |
| Sun Pharmaceutical Industries INC. | $16.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Grabowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.